Anna Lepistö

Anna Lepistö

Auto-generated profile, based on publicly available information

Anna Lepistö

Applied Tumor Genomics, Research Programs Unit, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2015 in Nature Genetics
Verified
Journal Article
Closed access
RKRiku Katainen
Riku Katainen
KDKashyap Dave
Kashyap Dave
EPEsa Pitkänen
Esa Pitkänen
KPKimmo Palin
Kimmo Palin
TKTeemu Kivioja
Teemu Kivioja
LALauri A Aaltonen
Lauri A Aaltonen

14 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPhilip J. Law
Philip J. Law
MTMaria Timofeeva
Maria Timofeeva
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
PBPeter Broderick
Peter Broderick
JSJames Studd
James Studd
MDMalcolm G. Dunlop
Malcolm G. Dunlop
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention.

27 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AWAnja Wagner
Anja Wagner
SAStefan Aretz
Stefan Aretz
AAAnnika Auranen
Annika Auranen
Marco BrunoMarco Bruno
Marco Bruno
Giulia Martina CavestroGiulia Martina Cavestro
Giulia Martina Cavestro
GMGabriela Möslein
Gabriela Möslein
The scientific data to guide the management of Peutz–Jeghers syndrome (PJS) are sparse. The available evidence has been reviewed and discussed by diverse medical specialists in the field of PJS to update the previous guideline from 2010 and formulate a revised practical guideline for colleagues managing PJS patients. Methods: Literature searches were performed using MEDLINE, Embase, and Cochrane. Evidence levels and recommendation strengths were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). A Delphi process was followed, with consensus being reached when ≥80% of the voting guideline committee members agreed. Recommendations and statements: The only recent guidelines available were for gastrointestinal and pancreatic management. These were reviewed and endorsed after confirming that no more recent relevant papers had been published. Literature searches were performed for additional questions and yielded a variable number of relevant papers depending on the subject addressed. Additional recommendations and statements were formulated. Conclusions: A decade on, the evidence base for recommendations remains poor, and collaborative studies are required to provide better data about this rare condition. Within these restrictions, multisystem, clinical management recommendations for PJS have been formulated.

1 October 2017 in European Journal of Cancer
Verified
Journal Article
Open access
SMSebastian May-Wilson
Sebastian May-Wilson
ASAmit Sud
Amit Sud
PLPhilip J. Law
Philip J. Law
KPKimmo Palin
Kimmo Palin
STSari Tuupanen
Sari Tuupanen
Richard HoulstonRichard Houlston
Richard Houlston
While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate associations between polyunsaturated (PUFA), monounsaturated (MUFA) and saturated FAs (SFAs) and CRC risk. We analysed genotype data on 9254 CRC cases and 18,386 controls of European ancestry. Externally weighted polygenic risk scores were generated and used to evaluate associations with CRC per one standard deviation increase in genetically defined plasma FA levels. Risk reduction was observed for oleic and palmitoleic MUFAs (OROA = 0.77, 95% CI: 0.65-0.92, P = 3.9 × 10-3; ORPOA = 0.36, 95% CI: 0.15-0.84, P = 0.018). PUFAs linoleic and arachidonic acid had negative and positive associations with CRC respectively (ORLA = 0.95, 95% CI: 0.93-0.98, P = 3.7 × 10-4; ORAA = 1.05, 95% CI: 1.02-1.07, P = 1.7 × 10-4). The SFA stearic acid was associated with increased CRC risk (ORSA = 1.17, 95% CI: 1.01-1.35, P = 0.041). Results from our analysis are broadly consistent with a pro-inflammatory FA profile having a detrimental effect in terms of CRC risk.

1 April 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CEChristoph Engel
Christoph Engel
AAAysel Ahadova
Aysel Ahadova
TSToni Seppälä
Toni Seppälä
SAStefan Aretz
Stefan Aretz
MBMarloes Bigirwamungu-Bargeman
Marloes Bigirwamungu-Bargeman
HVHans F. Vasen
Hans F. Vasen

29 January 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
POPia Osterlund
Pia Osterlund
TSTapio Salminen
Tapio Salminen
LSLeena-Maija Soveri
Leena-Maija Soveri
RKRaija Kallio
Raija Kallio
IKIlmo Kellokumpu
Ilmo Kellokumpu
HIHelena Isoniemi
Helena Isoniemi
Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the assessment of resectability upfront and twice during first-line therapy by the multidisciplinary team (MDT) at Helsinki tertiary referral centre. The primary outcome was resection rates and survival. In 2012–2018, 1086 patients were included. Median follow-up was 58 months. Multiple metastatic sites were present in 500 (46%) patients at baseline and in 820 (76%) during disease trajectory. In MDT assessments, 447 (41%) were classified as resectable, 310 (29%) upfront and 137 (18%) after conversion therapy. Six-hundred and ninety curative intent resections or local ablative therapies (LAT) were performed in 399 patients (89% of 447 resectable). Multiple metastasectomies for multisite or later developing metastases were performed in 148 (37%) patients. Overall, 414 liver, 112 lung, 57 peritoneal, and 107 other metastasectomies were performed. Median OS was 80·4 months in R0/1-resected (HR 0·15; CI95% 0·12–0·19), 39·1 months in R2-resected/LAT (0·39; 0·29–0·53) patients, and 20·8 months in patients treated with “systemic therapy alone” (reference), with 5-year OS rates of 66%, 40%, and 6%, respectively. Repeated centralized MDT assessment in real-world metastatic CRC patients generates high resectability (41%) and resection rates (37%) with impressive survival, even when multisite metastases are present or develop later. The funders had no role in the study design, analysis, and interpretation of the data or writing of this report.